Incyte signals $5.21B-$5.30B 2026 net sales outlook as Opzelura guidance rises to $1.10B-$1.12B
Incyte signals $5.21B-$5.30B 2026 net sales outlook as Opzelura guidance rises to $1.10B-$1.12B（摘要待生成）
Incyte (INCY) Q3 2026 Earnings Call Transcript
Incyte (INCY) Q3 2026 Earnings Call Transcript（摘要待生成）
What Incyte (INCY) Said on Its Q3 Earnings Call - Yahoo Finance
What Incyte (INCY) Said on Its Q3 Earnings Call - Yahoo Finance（摘要待生成）
Incyte: Q3 Earnings Snapshot - Yahoo Finance
Incyte: Q3 Earnings Snapshot - Yahoo Finance（摘要待生成）
Genmab, Incyte team up to develop experimental colorectal cancer treatment
Genmab, Incyte team up to develop experimental colorectal cancer treatment（摘要待生成）
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised - Zacks Investment Research
INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised - Zacks Investment Research（摘要待生成）
Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply
Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply（摘要待生成）
Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer
Genmab and Incyte have entered into a clinical trial collaboration to evaluate the combination of petosemtamab and INCB161734 in patients with KRAS G12D-mutated metastatic colorectal cancer.
Genmab and Incyte clinical-trial collaboration in KRAS G12D-mutated colorectal cancer
On October 24, 2026, Genmab and Incyte announced a Phase 1/2 collaboration to study petosemtamab plus Incyte’s investigational KRAS G12D inhibitor INCB161734 and standard chemotherapy as first-line treatment for KRAS G12D-mutated mCRC. Genmab will conduct the study; Incyte will co-fund it and provide clinical supply of INCB161734.